Quantcast

Latest hypoglycemia Stories

2014-06-16 08:28:47

Algorithm in Development Maintained Glucose Above Hypoglycemic Levels Over 99% of Time in Feasibility Study CHESTERBROOK, Pa., June 16, 2014 /PRNewswire/ -- Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. Data from a clinical feasibility study demonstrated that the algorithm was capable of helping maintain glucose above hypoglycemic levels an average of 99.1 percent of the time for the 12 participants investigated, all...

2014-06-14 12:21:12

Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through...

2014-06-14 12:21:08

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus(®) (insulin glargine). Lowering of post-prandial glucose was measured as change...

2014-06-14 12:20:48

CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers FREMONT, Calif., June 14, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74(th) American...

2014-06-13 23:07:04

On June 11, the FDA announced that all BMB-BA006A Advocate Redi-Code+ blood glucose test strip lots, by Diabetic Supply of Suncoast Inc., are recalled due to labeling error. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) June 13, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Blood...

2014-06-13 12:24:42

Urgent Medical Device Voluntary Recall News Release DORADO, Puerto Rico, June 13, 2014 /PRNewswire/ -- On June 6(th) 2014 Diabetic Supply of Suncoast, Inc. initiated a nationwide voluntary recall of all BMB-BA006A Advocate Redi-Code+ blood glucose test strip lots manufactured by BroadMaster Bio-Tech Corp currently in the market place. The Advocate Redi-Code+ BMB-BA006A blood glucose test strips are being recalled due to a labeling error which could result in confusion about which meter models...

2014-05-19 08:28:38

FREMONT, Calif., May 19, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr. Peter Daddona, the company's Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 3(rd) International Conference on Microneedles, in Baltimore, Maryland. Dr. Daddona is an invited speaker...

2014-05-12 20:23:08

Meeting supports clear path to commercialization CHARLOTTESVILLE, Va., May 12, 2014 /PRNewswire/ -- InSpark Technologies, Inc. announced today the results of a recent meeting with the FDA regarding the development and regulatory strategy for Vigilant* diabetes management software. Vigilant is an iPhone-enabled software application that analyzes blood glucose data and provides feedback about daily patterns of hyperglycemia, hypoglycemia, glucose variability, and test frequency in...

2014-04-28 08:31:53

Pivotal Trial to Build on Previous Positive Studies; Aims to Further Demonstrate Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System in the ICU HAYWARD, Calif., April 28, 2014 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous monitoring systems for use in the intensive care unit (ICU), today announced the enrollment of the first patient in a pivotal, multi-center Investigational Device Exemption (IDE) clinical study of the...

2014-04-24 16:28:58

ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated. No Hypoglycemic Events or Treatment Related Adverse Events Observed JERUSALEM, April 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2...


Latest hypoglycemia Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related